Starpharma Holdings Limited (SPHRY)
USD 0.59
(0.0%)
USD 0.59
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 7.65 Million AUD | -70.43% |
| 2023 | 25.89 Million AUD | 0.37% |
| 2022 | 25.8 Million AUD | -11.67% |
| 2021 | 29.2 Million AUD | 13.82% |
| 2020 | 25.66 Million AUD | 19.38% |
| 2019 | 21.49 Million AUD | 13.21% |
| 2018 | 18.98 Million AUD | -12.82% |
| 2017 | 21.77 Million AUD | -24.36% |
| 2016 | 28.79 Million AUD | 31.69% |
| 2015 | 21.86 Million AUD | 28.78% |
| 2014 | 16.97 Million AUD | 95.05% |
| 2013 | 8.7 Million AUD | -50.81% |
| 2012 | 17.69 Million AUD | 28.71% |
| 2011 | 13.74 Million AUD | -1.57% |
| 2010 | 13.96 Million AUD | -13.47% |
| 2009 | 16.14 Million AUD | -19.84% |
| 2008 | 20.13 Million AUD | 4.19% |
| 2007 | 19.32 Million AUD | 39.54% |
| 2006 | 13.85 Million AUD | 33.35% |
| 2005 | 10.38 Million AUD | 43.11% |
| 2004 | 7.25 Million AUD | -17.36% |
| 2003 | 8.78 Million AUD | -5.07% |
| 2002 | 9.25 Million AUD | 65.71% |
| 2001 | 5.58 Million AUD | 257.56% |
| 2000 | -3.54 Million AUD | -51.56% |
| 1999 | -2.33 Million AUD | 8.0% |
| 1998 | -2.54 Million AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 11.38 Million AUD | 533.1% |
| 2024 Q3 | 5.43 Million AUD | -52.25% |
| 2024 Q4 | 5.43 Million AUD | 0.0% |
| 2024 FY | 22.25 Million AUD | -14.04% |
| 2024 Q1 | 1.79 Million AUD | -85.56% |
| 2023 FY | 25.89 Million AUD | 0.37% |
| 2023 Q1 | 1.92 Million AUD | -84.68% |
| 2023 Q2 | 13.13 Million AUD | 583.08% |
| 2023 Q4 | 12.45 Million AUD | 565.06% |
| 2023 Q3 | 1.87 Million AUD | -85.75% |
| 2022 Q3 | 1.76 Million AUD | -86.12% |
| 2022 Q1 | 1.66 Million AUD | -88.78% |
| 2022 FY | 25.8 Million AUD | -11.67% |
| 2022 Q2 | 12.72 Million AUD | 665.3% |
| 2022 Q4 | 12.55 Million AUD | 610.58% |
| 2021 Q3 | 1.7 Million AUD | -88.17% |
| 2021 FY | 29.2 Million AUD | 13.82% |
| 2021 Q2 | 14.4 Million AUD | 630.39% |
| 2021 Q1 | 1.97 Million AUD | -83.93% |
| 2021 Q4 | 14.81 Million AUD | 769.66% |
| 2020 Q2 | 13.38 Million AUD | 650.28% |
| 2020 Q4 | 12.27 Million AUD | 871.59% |
| 2020 Q1 | 1.78 Million AUD | -84.22% |
| 2020 Q3 | 1.26 Million AUD | -90.56% |
| 2020 FY | 25.66 Million AUD | 19.38% |
| 2019 FY | 21.49 Million AUD | 13.21% |
| 2019 Q2 | 3.96 Million AUD | 0.0% |
| 2019 Q4 | 11.3 Million AUD | 157.09% |
| 2019 Q1 | 3.96 Million AUD | 2.03% |
| 2019 Q3 | 4.39 Million AUD | 10.96% |
| 2018 FY | 18.98 Million AUD | -12.82% |
| 2018 Q1 | 3.73 Million AUD | -25.12% |
| 2018 Q4 | 3.88 Million AUD | 0.0% |
| 2018 Q3 | 3.88 Million AUD | 3.96% |
| 2018 Q2 | 3.73 Million AUD | 0.0% |
| 2017 FY | 21.77 Million AUD | -24.36% |
| 2017 Q4 | 4.99 Million AUD | 0.0% |
| 2017 Q3 | 4.99 Million AUD | 12.34% |
| 2017 Q1 | 4.44 Million AUD | -16.58% |
| 2017 Q2 | 4.44 Million AUD | 0.0% |
| 2016 Q1 | 6.88 Million AUD | 21.08% |
| 2016 Q3 | 6.76 Million AUD | -1.73% |
| 2016 Q4 | 5.32 Million AUD | -21.31% |
| 2016 Q2 | 6.88 Million AUD | 0.0% |
| 2016 FY | 28.79 Million AUD | 31.69% |
| 2015 Q4 | 5.68 Million AUD | 0.0% |
| 2015 FY | 21.86 Million AUD | 28.78% |
| 2015 Q1 | 4.63 Million AUD | -3.36% |
| 2015 Q2 | 4.63 Million AUD | 0.0% |
| 2015 Q3 | 5.68 Million AUD | 22.72% |
| 2014 FY | 16.97 Million AUD | 95.05% |
| 2014 Q4 | 4.79 Million AUD | 0.0% |
| 2014 Q3 | 4.79 Million AUD | 52.44% |
| 2014 Q2 | 3.14 Million AUD | 0.0% |
| 2014 Q1 | 3.14 Million AUD | 38.81% |
| 2013 Q3 | 2.26 Million AUD | 45.16% |
| 2013 Q4 | 2.26 Million AUD | 0.0% |
| 2013 Q1 | 1.56 Million AUD | 0.0% |
| 2013 FY | 8.7 Million AUD | -50.81% |
| 2013 Q2 | 1.56 Million AUD | 0.0% |
| 2012 FY | 17.69 Million AUD | 28.71% |
| 2011 FY | 13.74 Million AUD | -1.57% |
| 2010 FY | 13.96 Million AUD | -13.47% |
| 2009 FY | 16.14 Million AUD | -19.84% |
| 2008 FY | 20.13 Million AUD | 4.19% |
| 2007 FY | 19.32 Million AUD | 39.54% |
| 2006 FY | 13.85 Million AUD | 33.35% |
| 2005 FY | 10.38 Million AUD | 43.11% |
| 2004 FY | 7.25 Million AUD | -17.36% |
| 2003 FY | 8.78 Million AUD | -5.07% |
| 2002 FY | 9.25 Million AUD | 65.71% |
| 2001 FY | 5.58 Million AUD | 257.56% |
| 2000 FY | -3.54 Million AUD | -51.56% |
| 1999 FY | -2.33 Million AUD | 8.0% |
| 1998 FY | -2.54 Million AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Neon Bloom, Inc. | 389.56 Thousand USD | -1865.521% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -191.415% |
| Biomind Labs Inc. | 994.18 Thousand USD | -670.181% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 92.291% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -13.977% |
| Skye Bioscience, Inc. | 13.54 Million USD | 43.481% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -310.702% |
| Mesoblast Limited | 5.9 Million USD | -29.736% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 30728.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -51.863% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 52.174% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -317.254% |
| GB Sciences, Inc. | 1.42 Million USD | -439.032% |
| MultiCell Technologies, Inc. | 567.42 USD | -1349341.331% |
| Alpha Cognition Inc. | 9.7 Million USD | 21.107% |
| HST Global, Inc. | 140.9 Thousand USD | -5334.081% |
| CSL Limited | 3.44 Billion USD | 99.778% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Agentix Corp. | 1.37 Million USD | -458.19% |
| Halberd Corporation | 74.84 Thousand USD | -10130.886% |
| Enzolytics Inc. | 2.17 Million USD | -251.318% |
| Resverlogix Corp. | 12.71 Million USD | 39.766% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -109.74% |
| argenx SE | 1.53 Billion USD | 99.501% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -633.429% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 69.019% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -124.877% |
| Bioxytran, Inc. | 3.82 Million USD | -100.437% |
| Zenith Capital Corp. | 8.94 Million USD | 14.38% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -211.854% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -4364.489% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -298.614% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.072% |
| Kadimastem Ltd | 2.41 Million USD | -217.703% |
| Helix BioMedix, Inc. | 1.97 Million USD | -288.279% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -335.136% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 29.539% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 12.783% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -73.68% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | -104.382% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1339.389% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -4119.081% |
| Q BioMed Inc. | 3.43 Million USD | -122.806% |
| LadRx Corporation | 3.81 Million USD | -100.877% |
| Cell Source, Inc. | 4.32 Million USD | -77.026% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -1742.933% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -729.119% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 86.67% |
| Itoco Inc. | 919.14 Thousand USD | -733.059% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -80.657% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -580.677% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -218.387% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -584.272% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -384.818% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | -4.743% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -43852.701% |
| NovAccess Global Inc. | 2.46 Million USD | -210.407% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -30322.345% |
| BioStem Technologies, Inc. | 22.97 Million USD | 66.672% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -3379.221% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -473.373% |
| Qrons Inc. | 643.67 Thousand USD | -1089.572% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -439.304% |
| SYBLEU INC | 160.87 Thousand USD | -4659.566% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -243.382% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1053.163% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -729.119% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -321.567% |
| Affymax, Inc. | 39.38 Million USD | 80.559% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1280.769% |
| International Stem Cell Corporation | 5.27 Million USD | -45.267% |
| CytoDyn Inc. | 18.05 Million USD | 57.598% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -14445.42% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -37539.483% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 78.887% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -373.239% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -940.587% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -146.127% |
| Neutra Corp. | 243.82 Thousand USD | -3040.419% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 56.138% |
| PureTech Health plc | 144.59 Million USD | 94.705% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 62.63% |
| IXICO plc | 4.7 Million USD | -62.673% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 12.959% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 93.497% |
| CSL Limited | 3.89 Billion USD | 99.803% |
| Cellectis S.A. | 97.32 Million USD | 92.132% |